Histologic improvement following treatment with once weekly pegylated interferon alfa-2a (Pegasys™) and thrice weekly interferon alfa-2a (Roferon™)in patients with chronic hepatitis C and compensated cirrhosis.

被引：2
|
作者：
Balart, LA
Lee, SS
Schiffman, M
Reindollar, R
Minuk, G
Pockros, P
Hoffman, J
Depamphilis, J
机构：
[1] LSU, Hlth Sci Ctr, New Orleans, LA USA
[2] Univ Calgary, Calgary, AB, Canada
[3] Carolinas Ctr Liver Dis, Charlotte, NC USA
[4] Hoffmann La Roche, Nutley, NJ USA
来源：
GASTROENTEROLOGY | 2000年 / 118卷 / 04期
关键词：
D O I：
10.1016/S0016-5085(00)85987-9
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
978
引用
收藏
页码：A961 / A961
页数：1
相关论文
共 50 条
  • [1] Histologic improvement following treatment with once weekly pegylated interferon alfa-2a (Pegasys™) and thrice weekly interferon alfa-2a (Roferon™) in patients with chronic hepatitis C without cirrhosis.
    Reddy, KR
    Shiffman, M
    Reindollar, R
    Fried, M
    Pockros, P
    Hoffman, J
    DePamphilis, J
    [J]. GASTROENTEROLOGY, 2000, 118 (04) : A945 - A945
  • [2] Pegylated (40kDa) interferon alfa-2a (pegasys™) is superior to interferon alfa-2a (roferon-A®) in improving posttreatment histologic outcome in chronic hepatitis C patients 1584.
    Heathcote, EJ
    Balart, LA
    Shiffman, ML
    Pockros, PJ
    Lee, SS
    Reddy, KR
    Minuk, YG
    Bain, V
    Sherman, M
    Wright, TL
    Reindollar, RW
    Brunda, MJ
    [J]. HEPATOLOGY, 2000, 32 (04) : 223A - 223A
  • [3] Enhanced efficacy of pegylated (40kDa) interferon alfa-2A (Pegasys™) compared with interferon alfa-2A (Roferon-A™) for chronic hepatitis C in Blacks.
    Shiffman, ML
    Fromm, H
    Mills, P
    Moonka, DK
    Fried, MW
    Berg, C
    Sherman, M
    Smith, C
    Marsano, L
    Reddy, KR
    Brunda, MJ
    DePamphilis, J
    [J]. HEPATOLOGY, 2000, 32 (04) : 348A - 348A
  • [4] Treatment of haemodialysis patients with chronic hepatitis C using pegylated interferon alfa-2A (Pegasys)
    Sim, N. Zulkarnain
    Chiu, A.
    Wong, H. S.
    [J]. NEPHROLOGY, 2008, 13 : A53 - A53
  • [5] Evaluation of the safety and efficacy of once-weekly peg/interferon alfa-2a (PEGASYS™) for chronic hepatitis C.: A multinational, randomized study
    Zeuzem, S
    Feinman, SV
    Rasenack, J
    Heathcote, EJ
    Lai, MY
    Gane, E
    O'Grady, J
    Reichen, J
    Brunda, MJ
    [J]. JOURNAL OF HEPATOLOGY, 2000, 32 : 29 - 29
  • [6] Treatment of chronic hepatitis C with pegylated interferon alfa-2a plus ribavirin in hemophiliac patients
    Malekzadeh, R
    Merat, S
    Sohrabpour, AA
    Khaleghi, S
    Samimi-Rad, K
    [J]. GASTROENTEROLOGY, 2004, 126 (04) : A431 - A431
  • [7] Twelve weeks of follow-up is sufficient for the determination of sustained virologic response tin patients with chronic hepatitis C treated with pegylated (40KDA) interferon alfa-2a (Pegasys™) and interferon alfa-2a (Roferon-A®).
    Zeuzem, S
    Heathcote, EJ
    Shiffman, ML
    Wright, TL
    Bain, VG
    Sherman, M
    Feinman, SV
    Fried, MW
    Rasenack, J
    Jensen, DM
    Lin, A
    Hoffman, JH
    [J]. HEPATOLOGY, 2000, 32 (04) : 356A - 356A
  • [8] Pegylated Interferon Alfa-2a Monotherapy for Hemodialysis Patients with Acute Hepatitis C
    Liu, Chen-Hua
    Liang, Cheng-Chao
    Liu, Chun-Jen
    Lin, Jou-Wei
    Chen, Shih-I
    Hung, Peir-Haur
    Tsai, Hung-Bin
    Lai, Ming-Yang
    Chen, Pei-Jer
    Chen, Ding-Shinn
    Kao, Jia-Horng
    [J]. CLINICAL INFECTIOUS DISEASES, 2010, 51 (05) : 541 - 549
  • [9] PEGYLATED INTERFERON ALFA-2A MONOTHERAPY FOR HEMODIALYSIS PATIENTS WITH ACUTE HEPATITIS C
    Liu, Chen-Hua
    Liang, Cheng-Chao
    Liu, Chun-Jen
    Hsu, Shih-Jer
    Chen, Shih-I
    Tsai, Hung-Bin
    Hung, Peir-Haur
    Lin, Jou-Wei
    Lai, Ming-Yang
    Chen, Pei-Jer
    Chen, Jun-Herng
    Chen, Ding-Shinn
    Kao, Jia-Horng
    [J]. HEPATOLOGY, 2009, 50 (04) : 692A - 692A
  • [10] Peginterferon alfa-2a (Pegasys) for chronic hepatitis C
    不详
    [J]. MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2003, 45 (1151): : 19 - 20
12345